There are 19 resources available
Rising PSA and detectable PSA after radical local treatment: Prognosis, indications for salvage local treatments, adjuvant vs salvage treatments
Presenter: A. Bossi, FR
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Use of early vs deferred systemic treatments in biochemical failures and in M0 CRPC
Presenter: K. Fizazi, FR
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: S. Gillessen, CH
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Oligo-metastatic treatment: what treatment?
Presenter: A. Bossi, FR
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Participant Clinical Case Discussion: A case of Docetaxel vs Enzalutamide
Presenter: H. Dearden, UK
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
PARP inhibitors and experimental treatments for mCRPC
Presenter: K. Fizazi, FR
Session: Session 4 - Metastatic castration-resistant disease
Resources:
Slides
Webcast
PSMA in diagnostic and therapy
Presenter: A-L. Giraudet, FR
Session: Session 4 - Metastatic castration-resistant disease
Resources:
Slides
Webcast
Metastatic CRPC: Current treatment
Presenter: S. Gillessen, CH
Session: Session 4 - Metastatic castration-resistant disease
Resources:
Slides
Webcast
Participant Clinical Case Discussion: Poliomyelitis sequelae and multiple lines of treatment (11)
Presenter: Endre Mate, RO
Session: Session 4 - Metastatic castration-resistant disease
Resources:
Slides
Webcast